Analyst Report: ELV

1. EXECUTIVE SUMMARY

Elevance Health, Inc. (NYSE: ELV) plummeted -10.10% over the week ending July 20, 2026, falling from a 52-week high of $436.24 on July 14 to close at $382.23 on July 20. The steep selloff was triggered by the company’s Q2 2026 financial report on July 15. Although headline numbers showed a significant top- and bottom-line beat ($7.45 adjusted EPS vs. $6.21 consensus), institutional investors immediately looked past the headline beat. The quality of earnings was heavily impaired by an $0.80 per share non-recurring below-the-line net investment valuation benefit, masking severe margin erosion in the core insurance business. Health Benefits operating margin compressed 170 basis points year-over-year to 2.1%, driven by an 80 bps surge in the Benefit Expense Ratio (MLR) to 89.7% amid elevated Government healthcare utilization. Management’s revelation that Medicaid will remain deeply unprofitable in 2026 (operating margin of -1.75%), combined with plans to exit underperforming Medicaid markets (including Washington, D.C.), raised fundamental concerns about state rate lag and organic growth. While insider buying at the $366 level provides a short-term floor, the structural headwinds in government programs represent a multi-quarter margin overhang.

2. THE CATALYST (CRITICAL)

The primary catalyst for the stock collapse was Elevance Health’s Q2 2026 earnings release and conference call on July 15, 2026.

Detailed Breakout of the Earnings Event:

• Headline vs. Core Reality: Elevance reported Q2 2026 operating revenue of $49.83 billion (+0.8% YoY) vs. $48.63B expected, and adjusted diluted EPS of $7.45 vs. $6.21 consensus (+19.97% surprise). However, management disclosed that ~$0.80 per share of the $1.24 beat was attributable to non-recurring below-the-line items (primarily net investment valuation adjustments). Core operational beat was negligible.
• Margin Compression & Benefit Expense Ratio (MLR): The Benefit Expense Ratio rose 80 basis points YoY to 89.7% (up from 88.9% in Q2 2025) due to elevated medical cost trends, inpatient/outpatient surgical volume, and specialty pharmacy spend in Government lines. Consolidated operating margin fell from 4.9% to 3.5%.
• Medicaid Margins & Market Exits: Management confirmed that 2026 is the "trough year" for Medicaid, reaffirming a negative full-year segment operating margin of -1.75%. Management announced a mutual agreement to exit the Washington, D.C. Medicaid market in summer 2026 and signaled targeted exits from additional unprofitable state Medicaid programs over the next 12–18 months where state reimbursement rates fail to match member acuity.
• Underwhelming Guidance Increase: Elevance raised its FY 2026 adjusted EPS guidance floor to "at least $27.00" (from "at least $26.75"). The $0.25 floor lift was viewed as disappointing relative to the $1.24 quarterly headline beat, implying margin pressure in H2 2026.
• Membership Attrition: Total medical membership contracted by 469,000 members sequentially (-1.5%) to 44.9 million as of June 30, 2026, due to commercial fee-based customer transitions and redetermination/attrition in Individual ACA and Medicaid.

Key Dates & Sources:

• July 14, 2026: Stock peaks at an all-time/52-week high of $436.24 on pre-earnings optimism.
• July 15, 2026 (8:30 AM ET): Q2 earnings call held. Stock plunges -8.54% to close at $390.33.
• July 16, 2026: Selling pressure accelerates, pushing ELV down another -4.48% to $372.85 (intraday low $370.00).
• July 17, 2026: SEC Form 4 filings reveal insider purchases: CEO Gail Boudreaux purchased 2,725 shares at weighted average $366.41 ($1.0M), and Board Chairman Ramiro G. Peru purchased 1,000 shares at $366.05 ($366K).

3. COMPANY PROFILE

• Official Company Name: Elevance Health, Inc. (formerly Anthem, Inc., renamed June 2022).
• Core Business: Elevance Health is one of the nation's largest managed healthcare and health benefits companies. It operates through two primary divisions: Health Benefits (commercial and government insurance plans under Anthem Blue Cross Blue Shield and Wellpoint) and Carelon (healthcare service enablement including CarelonRx pharmacy benefit management and Carelon Services).
• Key Metrics:
  • Market Capitalization: ~$82.1 Billion (as of July 20, 2026 close at $382.23).
  • Sector / Industry: Healthcare / Managed Healthcare & Health Insurance.
  • Key Competitors: UnitedHealth Group (UNH), Humana Inc. (HUM), Centene Corporation (CNC), Molina Healthcare (MOH), CVS Health / Aetna (CVS).
• Performance Context:
  • 52-Week Range: $273.71 – $436.24.
  • Recent Trailing Price Action: ELV traded near multi-year highs before the earnings collapse, underperforming peers post-earnings due to heavy exposure to Medicaid margin compression.

4. DEEP DIVE ANALYSIS

Fundamentals vs. Market Overreaction

The -10.10% price correction is fundamentally justified in the short term, though slightly exaggerated by momentum unwinding after touching 52-week highs ($436.24) right before the release.

The quality of Q2 earnings was poor. Removing the $0.80 net investment valuation gain leaves core operational EPS at ~$6.65, barely meeting consensus. Furthermore, Medicaid generating a negative 1.75% operating margin for full-year 2026 highlights that state rate adjustments are failing to keep pace with higher member utilization post-pandemic redeterminations.

Competitor Trends & Sector Dynamics

The selloff in ELV coincided with broader distress across the managed care space:

• UnitedHealth Group (UNH): Reported severe profit pressure, warning of elevated medical utilization, which dragged down sector multiples.
• Centene (CNC) & Molina (MOH): Centene had previously pulled full-year guidance due to surging Medicaid claims, and Molina dropped ~9% in tandem with Elevance’s earnings announcement as investors feared systemic Medicaid rate inadequacy.
• Sector Trend: Health insurers are stuck between persistent medical cost inflation (orthopedics, outpatient procedures, GLP-1/specialty drugs) and delayed state/CMS reimbursement rate adjustments.

Strategic Direction: Exiting Unprofitable Markets

Elevance's decision to exit the D.C. Medicaid market and prep further contract drops over 12–18 months is a necessary capital allocation shift to protect long-term ROIC. However, shrinking premium revenue in government programs temporarily removes a primary top-line growth driver.

Bull vs. Bear Case

                      ┌─────────────────────────────────────────┐
                      │            ELEVANCE HEALTH              │
                      └────────────────────┬────────────────────┘
                                           │
             ┌─────────────────────────────┴─────────────────────────────┐
             ▼                                                           ▼
     ┌───────────────┐                                           ┌───────────────┐
     │   BULL CASE   │                                           │   BEAR CASE   │
     └───────┬───────┘                                           └───────┬───────┘
             │                                                           │
 ├─ Carelon non-insurance services                           ├─ Medicaid margin recovery stays
 │  growing (+6.0% YoY, $19.2B rev)                    │  stuck below zero into 2027
 │                                                               │
 ├─ Aggressive portfolio trimming                            ├─ Regulatory/CMS rate squeeze in
 │  exiting loss-making states                         │  Medicare Advantage & ACA
 │                                                               │
 ├─ Strong executive buys at $366                            ├─ Ongoing membership attrition
 │  (CEO & Chairman purchased shares)                  │  (-469k QoQ sequential drop)
 │                                                               │
 └─ Target 12%+ EPS growth baseline                         └─ Higher medical costs from outpatient
    reaffirmed for FY 2027                              │  procedures and pharmacy

5. TECHNICAL SNAPSHOT

• Price Movement: Shares dropped from a pre-earnings high of $436.24 on July 14 down to $365.38 intraday on July 17, before rebounding modestly to $382.23 on July 20.
• Key Support Levels:
  • $365.00 – $366.00: Immediate support zone tested on July 17 (intraday low $365.38; CEO/Chairman insider buy range $366.05–$366.41).
  • $350.00: Key psychological support and lower trendline bound.
  • $273.71: 52-week low floor.
• Key Resistance Levels:
  • $390.00 – $395.00: Post-earnings breakdown point and pre-earnings consolidation level.
  • $415.00 – $420.00: Major overhead supply zone.
  • $436.24: 52-Week High.
• Volume Analysis: Trading volume surged to 3.85 million shares on July 15 (more than double the ~1.7M daily average), confirming strong institutional distribution following the Q2 report.

6. RISK FACTORS

• Medicaid Rate Disconnect: State rate increases may continue lagging medical cost inflation (outpatient surgery, specialty drugs, behavioral health). If state rate adjustments for 2027 remain insufficient, Medicaid operating margins could fail to rebound from the -1.75% trough.
• Elevated Utilization Trends: Continued elevated medical utilization across senior and government membership could push the Benefit Expense Ratio above 90.0% in Q3/Q4 2026.
• Government & Regulatory Scrutiny: Increased CMS audits on Medicare Advantage risk adjustments (Elevance recently remitted $342M to CMS related to historical risk adjustment data submissions).
• Execution Risk on Market Exits: Contract terminations in Medicaid (e.g., Washington, D.C.) carry restructuring costs and potential disruption to Carelon cross-selling opportunities.

7. ACTIONABLE OUTLOOK

Short-Term (1–2 Weeks): Range-Bound Consolidation

Expect ELV to trade in a tight range between $370.00 and $395.00. The open-market insider purchases by CEO Gail Boudreaux ($1M) and Chairman Ramiro Peru at ~$366 on July 17 establish a firm short-term floor. Technical bounce attempts toward $390–$395 will encounter heavy overhead resistance from trapped post-earnings buyers.

Medium-Term (1–3 Months): Unremarkable Recovery

Price action will depend on peer earnings disclosures and state-level Medicaid rate updates in Q3. Without upward revisions to Medicaid margin expectations, upside will remain capped below $410. The company’s CarelonRx and Carelon Services divisions (+6% growth) offer defensive cash flow, supporting the revised $27.00 FY26 EPS floor.

Long-Term Thesis: Intact but Re-Rated Lower

• Rating: HOLD / NEUTRAL ACCUMULATION ON DIPS.
• Core View: Elevance’s long-term business model remains structurally sound, anchored by its commercial Blue Cross Blue Shield moat and high-margin Carelon services unit. Management’s commitment to re-establishing a 12%+ adjusted EPS growth trajectory in FY 2027 off the 2026 baseline is achievable once non-performing Medicaid contracts are pruned. However, until medical loss ratios stabilize in government lines, multiple expansion will be limited. Investors should wait for signs of MLR stabilization before building aggressive long positions.